Is PAVmed, Inc. overvalued or undervalued?

As of 24 October 2025, PAVmed, Inc. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics. Key ratios include a Price to Book Value of 0.23, an EV to EBIT of -0.43, and a ROE of 92.94%. In comparison, Delcath Systems, Inc. is considered expensive with a P/E of 68.06, while BioSig Technologies, Inc. shows a negative EV to EBITDA of -4.99.
The stock has significantly underperformed relative to the S&P 500, with a year-to-date return of -34.92% compared to the S&P 500's 15.47%. This stark contrast reinforces the notion that PAVmed, Inc. is currently overvalued in the market.